RxDoctor Payments Data

Srinivas Koneru, MD

Cardiovascular Disease · Sterling Heights, MINPI 1477599587

Payments from drug & device makers

$42,031in general payments, 2019–2025

Across 596 payments — averaging $70.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$26K
  • Medtronic$4K
  • Boston Scientific$3K
  • Abbott$3K
  • Johnson & Johnson$869
  • Novartis$793
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$1,2993%
  • Food & beverage$15,02336%
  • Education$2090%
  • Other$25,50061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,031 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$628,650
Medicare patients
902
Services billed
8,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban562$657,000
EntrestoSacubitril/Valsartan399$539,178
XareltoRivaroxaban169$180,620
JardianceEmpagliflozin99$116,915
FarxigaDapagliflozin Propanediol73$73,321
BrilintaTicagrelor78$67,066
ClopidogrelClopidogrel Bisulfate1,701$32,311
Ranolazine ErRanolazine267$28,818
Repatha SyringeEvolocumab30$23,913
Repatha SureclickEvolocumab23$17,079
Metoprolol Succinate787$14,582
NexlizetBempedoic Acid/Ezetimibe24$13,922
Praluent PenAlirocumab21$13,018
Atorvastatin Calcium849$11,471
Losartan Potassium530$7,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$184$657,000562 claims
NovartisEntresto$793$539,178399 claims
Johnson & JohnsonXarelto$869$180,620169 claims
AstraZenecaFarxiga, Brilinta$83$140,386151 claims
Boehringer IngelheimJardiance$147$116,91599 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$90$19,67437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →